Neurogene Inc. (NGNE)

Market Cap	394.33M
Revenue (ttm)	n/a
Net Income (ttm)	-36.32M
Shares Out	12.85M
EPS (ttm)	2.93
PE Ratio	10.64
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,061
Open	30.96
Previous Close	31.17
Day's Range	30.33 - 31.38
52-Week Range	12.20 - 53.00
Beta	n/a
Analysts	Strong Buy
Price Target	43.00 (+40.57%)
Earnings Date	May 15, 2024

About NGNE

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquarter...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 91
• Stock Exchange: NASDAQ
• Ticker Symbol: NGNE

Analyst Forecast

According to 3 analysts, the average rating for NGNE stock is "Strong Buy." The 12-month stock price forecast is $43.0, which is an increase of 40.57% from the latest price.

Price Target

$43.0

(40.57% upside)

Analyst Consensus: Strong Buy